- Home
- SGMT vs CAST Comparison
SGMT vs CAST Comparison
Compare SGMT & CAST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$0.68
Company Overview
Basic Information| Metric | SGMT | CAST |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 194.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMT | CAST |
|---|---|---|
| Price | $6.76 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $26.13 | $6.00 |
| AVG Volume (30 Days) | ★ 742.9K | 223.5K |
| Earning Date | 05-14-2026 | 06-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $0.68 |
| 52 Week High | $11.41 | $4.90 |
Technical Indicators
Market Signals| Indicator | SGMT | CAST |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 29.83 |
| Support Level | $6.33 | $0.68 |
| Resistance Level | $7.39 | $1.99 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 33.91 | 4.23 |
Price Performance
Historical Comparison SGMT
CAST
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.